Matinas BioPharma Holdings terminated its engagement with a former financial advisor on November 3, 2026. The original agreement provided for up to $2.0 million in cash and $2.0 million in stock upon the closing of certain business combinations. In connection with the termination, the company paid the advisor $562,500 in cash and executed mutual releases subject to contingencies. Matinas BioPharma is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases.
